UPDATE: Goldman Sachs Maintains Neutral Rating, Raises PT for Vertex Pharmaceuticals

In a company update published earlier today, the Goldman Sachs Group, Inc. maintained its Neutral rating for Vertex Pharmaceuticals Incorporated VRTX and raised its price target from $40.00 to $60.00. Goldman Sachs went on to say “Following interim Ph2 data from Kalydeco and VX-809 combo, we are adding sales to our model (we assume a 60% chance of approval in F508del homozygous patients, 45% of CF population) and project adjusted peak sales of $2bn. We also increase our R&D, SG&A, and COGS expenses. As a result our 2013-2015 EPS estimates change to $4.78/$4.67/$2.14 from $4.99/$4.82/$1.24.” Vertex Pharmaceuticals Incorporated closed yesterday at $60.19.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsGoldman Sachs Group Inc.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!